Skip to Main Content
Table 1

Characteristics of five studies that investigated strategies taken by healthy BRCA1 or BRCA2 mutation carriers to reduce risk of breast cancer

StudyStudy populationLocation of studySample size of healthy mutation carriersMethod used to assess outcomeFollow-up periodChoice of risk reduction strategy
SurveillancePM
Botkin et al. (20) Females from an extended kindred known to carry a single BRCA1 mutation, recruited between 1995 and 1997, predominantly Mormons. Salt Lake City, UT, USA 37 In-person interview 12 months 100% (37) 0 % (0) 
     24 months 100% (37) 0% (0) 
Lerman et al. (21) Females from an extended BRCA1- or BRCA2-linked families, enrolled in research protocol from July 1994 to October 1997 Omaha, NE, USA 29 Telephone interview 12 months 97% (28) 3% (1) 
Lodder et al. (13) Females from families known to carry a BRCA1 or BRCA2 mutation and with a first-degree relative with breast or ovarian cancer, who underwent genetic testing, Department of Clinical Genetics, Erasmus University, from December 1995 to April 1998 Rotterdam, the Netherlands 26 In-person interview 12 months 46% (12) 54% (14) 
Meijers-Heijboer et al. (9) Females from families known to carry a BRCA1 or BRCA2 mutation, and with a first-degree relative with breast cancer or ovarian, who were seen at the Family Cancer Clinic and underwent BRCA1/2 testing, Department of Clinical Genetics, Erasmus University, from Jan 1, 1994 to Jan 1, 1998 Rotterdam, the Netherlands 68 Clinical records 12 months 53% (36) 47% (32) 
     For entire follow-up period (median = 21 months range = 10.0-61.0) 49% (33) 51% (35) 
Scheuer et al. (2) Females who enrolled in one of three follow-up studies (one for those of Ashkenazi origin) and received genetic testing at Memorial Sloan-Kettering Cancer Center, from June 1, 1995 to October 31, 2000 New York, NY, USA 194 Telephone interview plus clinical records and pathology reports Mean = 24.1 months; range = 1.6-66.0 85% (165) 15% (29) 
StudyStudy populationLocation of studySample size of healthy mutation carriersMethod used to assess outcomeFollow-up periodChoice of risk reduction strategy
SurveillancePM
Botkin et al. (20) Females from an extended kindred known to carry a single BRCA1 mutation, recruited between 1995 and 1997, predominantly Mormons. Salt Lake City, UT, USA 37 In-person interview 12 months 100% (37) 0 % (0) 
     24 months 100% (37) 0% (0) 
Lerman et al. (21) Females from an extended BRCA1- or BRCA2-linked families, enrolled in research protocol from July 1994 to October 1997 Omaha, NE, USA 29 Telephone interview 12 months 97% (28) 3% (1) 
Lodder et al. (13) Females from families known to carry a BRCA1 or BRCA2 mutation and with a first-degree relative with breast or ovarian cancer, who underwent genetic testing, Department of Clinical Genetics, Erasmus University, from December 1995 to April 1998 Rotterdam, the Netherlands 26 In-person interview 12 months 46% (12) 54% (14) 
Meijers-Heijboer et al. (9) Females from families known to carry a BRCA1 or BRCA2 mutation, and with a first-degree relative with breast cancer or ovarian, who were seen at the Family Cancer Clinic and underwent BRCA1/2 testing, Department of Clinical Genetics, Erasmus University, from Jan 1, 1994 to Jan 1, 1998 Rotterdam, the Netherlands 68 Clinical records 12 months 53% (36) 47% (32) 
     For entire follow-up period (median = 21 months range = 10.0-61.0) 49% (33) 51% (35) 
Scheuer et al. (2) Females who enrolled in one of three follow-up studies (one for those of Ashkenazi origin) and received genetic testing at Memorial Sloan-Kettering Cancer Center, from June 1, 1995 to October 31, 2000 New York, NY, USA 194 Telephone interview plus clinical records and pathology reports Mean = 24.1 months; range = 1.6-66.0 85% (165) 15% (29) 
Close Modal

or Create an Account

Close Modal
Close Modal